COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff. Learn more about guidelines for the resumption of live
(in-person) courses and conferences
effective July 1, 2021 and available COVID-19 online education and resources.
Bristol Myers Squib - Exhibitor


Company Website

Contact information

Monica Carlson
monica.carlson@bms.com
952-913-9266

Yvonne Holcomb
yvonne.holcomb@bms.com
651-231-6038

Virtual Exhibit Hall Home



At Bristol Myers Squib, we’re advancing blood cancer treatments that have transformational potential. And, we are building on the life-changing medicines we have brought forward, now representing the foundations of care. With an unmatched commitment, we’re taking clear steps to build a future of better care by collaborating with healthcare providers, innovators, industry partners and patient advocacy groups to address all aspects of treatment and support. 

Leveraging multiple treatment modalities and advanced science, we seek to address hematologic conditions head-on. We are exploring new treatment approaches that target key biological pathways and are expanding our understanding of immune cell therapy to improve patient outcomes. Our work in cell therapy allows us to potentially redefine the future of personalized medicine, with an advanced cell therapy program and a growing early-stage pipeline that expands cell and gene therapy targets and technologies.

With the most robust portfolio of treatments for patients with multiple myeloma, and continued expansion of treatment options for lymphoma and myeloid diseases, these advances have transformed how we treat blood disorders and have helped contribute to patients living longer and better than previously imagined. However, our work is not done. We will remain committed to supporting more patients across more blood diseases, by developing better treatment options, now into the future.

Additional Information:
Revlimid (lenalidomide)
Pomalyst (pomalidomide)
Abecma (idecabtagene vicleucel)
Thalomid (thalidomide)